Published by Josh White on 24th October 2016
(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday.
URL: http://www.digitallook.com/dl/news/story/25120459/...